Searchable abstracts of presentations at key conferences on calcified tissues

ba0002oc19 | Miscellaneous | ICCBH2013

New therapeutic approach in OI VI: suppression of bone resorption using the RANKL antibody denosumab

Hoyer-Kuhn Heike , Semler Oliver , Netzer Christian , Dotsch Jorg , Schonau Eckhard

Background: Osteogenesis imperfecta (OI) as a rare disease is characterized by reduced bone mass, increased fracture rate, bone deformities and skeletal pain.Currently patients are treated with i.v. bisphosphonates regardless of the underlying mutation.Recently the gene causing OI type VI was described (SERPINF-1, altered RANKL-pathway). This leads to a new understanding of the underlying pathophysiology and offered a new therapeut...

ba0007p138 | (1) | ICCBH2019

How early is early enough – Bisphosphonate treatment in Osteogenesis imperfecta

Hoyer-Kuhn Heike , Heistermann Johanna , Schonau Eckhard , Rehberg Mirko , Semler Oliver

Objective: Osteogenesis imperfecta is characterized by hereditary skeletal fragility. Bisphosphonates are the first line medical treatment in moderate and severe OI types III/IV. There is no consensus regarding treatment beginning and treatment regimen in the first years. Objective of the presented project was the evaluation of the therapeutic effect of 1 year of bisphosphonate treatment (BP; neridronate i.v. 2 mg/kg body weight every 3 months) on vertebral shape and mobility ...